EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of Novel Class of Phenylpyrazolo[3,4-d]pyrimidine-Based Analogs with Potent Anticancer Activity and Multitarget Enzyme Inhibition Supported by Docking Studies

Ahmed K B Aljohani, Waheed Ali Zaki El Zaloa, Mohamed Alswah iD, Mohamed A Seleem iD, Mohamed M Elsebaei iD, Ashraf H Bayoumi, Ahmed M El-Morsy iD, Mohammed Almaghrabi iD, Aeshah A Awaji, Ali Hammad, Marwa Alsulaimany iD, Hany E A Ahmed

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms241915026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Ahmed K B Aljohani und 11 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacognosy and Pharmaceutical Chemistry Department, College of Pharmacy, Taibah University, Al-Madinah Al-Munawarah 41477, Saudi Arabia. Hauptthemen laut MEDLINE: Lung Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Taibah University, Deputyship for Research and Innovation, Ministry of Education, Saudi Arabia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Phenylpyrazolo[3,4-d]pyrimidine is considered a milestone scaffold known to possess various biological activities such as antiparasitic, antifungal, antimicrobial, and antiproliferative activities. In addition, the urgent need for selective and potent novel anticancer agents represents a major route in the drug discovery process. Herein, new aryl analogs were synthesized and evaluated for their anticancer effects on a panel of cancer cell lines: MCF-7, HCT116, and HePG-2. Some of these compounds showed potent cytotoxicity, with variable degrees of potency and cell line selectivity in antiproliferative assays with low resistance. As the analogs carry the pyrazolopyrimidine scaffold, which looks structurally very similar to tyrosine and receptor kinase inhibitors, the potent compounds were evaluated for their inhibitory effects on three essential cancer targets: EGFRWT, EGFRT790M, VGFR2, and Top-II. The data obtained revealed that most of these compounds were potent, with variable degrees of target selectivity and dual EGFR/VGFR2 inhibitors at the IC50 value range, i.e., 0.3–24 µM. Among these, compound 5i was the most potent non-selective dual EGFR/VGFR2 inhibitor, with inhibitory concentrations of 0.3 and 7.60 µM, respectively. When 5i was tested in an MCF-7 model, it effectively inhibited tumor growth, strongly induced cancer cell apoptosis, inhibited cell migration, and suppressed cell cycle progression leading to DNA fragmentation. Molecular docking studies were performed to explore the binding mode and mechanism of such compounds on protein targets and mapped with reference ligands. The results of our studies indicate that the newly discovered phenylpyrazolo[3,4-d]pyrimidine-based multitarget inhibitors have significant potential for anticancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsAntineoplastic AgentsHumansStructure-Activity RelationshipErbB ReceptorsCell ProliferationMolecular Docking SimulationDrug Screening Assays, AntitumorProtein Kinase InhibitorsMutationAntimetabolitesPyrimidinesMolecular StructureCell Line, Tumor

Stichwörter der Autor:innen

EGFRVGFRapoptosiscell cycle analysisdockingphenylpyrazolo[3,4-d]pyrimidinetyrosine kinase

Substanzen

ErbB ReceptorsProtein Kinase InhibitorsAntineoplastic AgentsAntimetabolitesPyrimidines

Autor:innen und Institutionen

  • Pharmacognosy and Pharmaceutical Chemistry Department, College of Pharmacy, Taibah University, Al-Madinah Al-Munawarah 41477, Saudi Arabia.
  • Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Al-Azhar University, Cairo 11884, Egypt.
  • Pharmaceutical Chemistry Department, College of Pharmacy, The Islamic University, Najaf 54001, Iraq.
  • Department of Biology, Faculty of Science, University College of Taymaa, University of Tabuk, Tabuk 71491, Saudi Arabia.

ORCID-Profile: Mohamed Alswah, Mohamed A Seleem, Mohamed M Elsebaei, Ahmed M El-Morsy, Mohammed Almaghrabi, Marwa Alsulaimany

Förderung

  • Taibah University
  • Deputyship for Research and Innovation, Ministry of Education, Saudi Arabia

Zitieren

APA

Aljohani, A. K. B., El Zaloa, W. A. Z., Alswah, M., Seleem, M. A., Elsebaei, M. M., Bayoumi, A. H., El-Morsy, A. M., Almaghrabi, M., Awaji, A. A., Hammad, A., Alsulaimany, M., & Ahmed, H. E. A. (2023). Development of Novel Class of Phenylpyrazolo[3,4-d]pyrimidine-Based Analogs with Potent Anticancer Activity and Multitarget Enzyme Inhibition Supported by Docking Studies. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241915026

Vancouver

Aljohani AKB, El Zaloa WAZ, Alswah M, Seleem MA, Elsebaei MM, Bayoumi AH, et al. Development of Novel Class of Phenylpyrazolo[3,4-d]pyrimidine-Based Analogs with Potent Anticancer Activity and Multitarget Enzyme Inhibition Supported by Docking Studies. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241915026

BibTeX
@article{Aljohani2023,
  author = {Aljohani, Ahmed K B and El Zaloa, Waheed Ali Zaki and Alswah, Mohamed and Seleem, Mohamed A and Elsebaei, Mohamed M and Bayoumi, Ashraf H and El-Morsy, Ahmed M and Almaghrabi, Mohammed and Awaji, Aeshah A and Hammad, Ali and Alsulaimany, Marwa and Ahmed, Hany E A},
  title = {Development of Novel Class of Phenylpyrazolo[3,4-d]pyrimidine-Based Analogs with Potent Anticancer Activity and Multitarget Enzyme Inhibition Supported by Docking Studies},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms241915026}
}
Kostenlos starten →